Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
07 August 2014Website:
http://www.t2biosystems.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
pre-market | 7 min agoDividend
Analysts recommendations
Institutional Ownership
TTOO Latest News
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the third quarter 2024 and business updates after market close on Thursday, November 14, 2024.
T2 Biosystems, Inc. (NASDAQ:TTOO ) Business Update Conference Call October 10, 2024 4:30 PM ET Company Participants Trip Taylor - IR John Sperzel - Chairman and CEO Conference Call Participants Eduardo Martinez - H.C. Wainwright Operator Good day, everyone.
LEXINGTON, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will host a business update call to provide additional details on recent developments after market close at 4:30pm ET on Thursday October 10, 2024. On the call management also plans to address select questions from shareholders that can be submitted in advance to the investor relations team at [email protected] .
LEXINGTON, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has successfully defended against an opposition filed against a key patent for its direct-from-whole blood detection method in the European Union.
LEXINGTON, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in two upcoming investor conferences in August 2024:
LEXINGTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of a territory exclusive distribution agreement in Malaysia and Indonesia. Under the terms of the agreement, T2 Biosystems will sell the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel through the newly appointed distributor.
LEXINGTON, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the second quarter 2024 and business updates after market close on Monday, July 29, 2024.
Shares of T2 Biosystems (NASDAQ: TTOO ) stock are rising higher after the medical diagnostics company disclosed that the Nasdaq Hearings Panel had provided it with an extension to regain compliance. T2 will have until May 20 to maintain a closing market capitalization of at least $35 million for at least 10 consecutive trading days.
T2 Biosystems Inc. (TTOO), a prominent player in the field of medical diagnostics, recently announced its financial results for the fourth quarter of 2023, signaling a pivotal moment for the company.
T2 Biosystems, Inc. (TTOO) Q4 2023 Earnings Call Transcript
What type of business is T2 Biosystems?
T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
What sector is T2 Biosystems in?
T2 Biosystems is in the Healthcare sector
What industry is T2 Biosystems in?
T2 Biosystems is in the Diagnostics & Research industry
What country is T2 Biosystems from?
T2 Biosystems is headquartered in United States
When did T2 Biosystems go public?
T2 Biosystems initial public offering (IPO) was on 07 August 2014
What is T2 Biosystems website?
https://www.t2biosystems.com
Is T2 Biosystems in the S&P 500?
No, T2 Biosystems is not included in the S&P 500 index
Is T2 Biosystems in the NASDAQ 100?
No, T2 Biosystems is not included in the NASDAQ 100 index
Is T2 Biosystems in the Dow Jones?
No, T2 Biosystems is not included in the Dow Jones index
When was T2 Biosystems the previous earnings report?
No data
When does T2 Biosystems earnings report?
Next earnings report date is not announced yet